Biogen acquires Apellis Pharmaceuticals for $5.6bn cash

Deal expands Biogen's rare-disease and immunology portfolio, with Apellis carrying a large acquisition premium

Briefing

Biogen has agreed to acquire Apellis Pharmaceuticals in an all-cash transaction valued at approximately $5.6 billion. The deal broadens Biogen's presence in immunology and rare-disease medicine, including kidney disorders, where Biogen already has a drug in development. Biogen is paying a significant premium for Apellis.

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, the companies announced on 31 March, in a move that extends Biogen's existing rare-disease franchise into immunology and kidney disorders.

Biogen was already developing a treatment targeting several kidney conditions, making Apellis a strategically complementary rather than diversifying acquisition. The deal carries a large premium to Apellis's pre-announcement valuation, according to reporting by MarketWatch, though precise per-share terms were not disclosed in available sources.

The transaction reinforces a broader trend among mid-to-large pharmaceutical companies of using acquisitions to replenish pipelines in high-value rare and orphan disease categories, where pricing power and regulatory exclusivity periods are more durable than in primary-care therapeutics.

Analysis

Biogen's $5.6bn all-cash bid for Apellis, following Merck's $6.7bn cash acquisition of Terns, confirms that large-cap pharma business development is accelerating into rare and orphan disease targets to replace patent-cliff revenues. Remaining standalone rare-disease names with advanced clinical assets, particularly those in nephrology and complement pathways, are now explicitly in play. Arrowhead Pharmaceuticals, ChemoCentryx precedents, and similar single-asset kidney or immune-mediated disease platforms become the nearest comparable acquisition targets.
The deal depletes Biogen's cash reserves at a moment when the macro environment, $115 Brent, 4.2% CPI trajectory, and no near-term Fed cuts, raises the opportunity cost of large cash deployments. If Biogen used leverage to fund any portion, spread widening on its investment-grade debt becomes a near-term watch item alongside the Sysco credit stress already in the market.
Apellis's premium validates the complement-pathway inhibitor class commercially. AstraZeneca's Ultomiris franchise and its orphan nephrology pipeline face a more competitive landscape as Biogen's commercial infrastructure now enters the same patient population. Biogen's rare-disease salesforce, already established in neurology and spinal muscular atrophy, gives Apellis's syfovre and systemic complement assets a distribution advantage that was previously a competitive gap.

Connected Events

M&A · 2 months ago

Merck buys Terns Pharmaceuticals for $6.7bn to shore up post-Keytruda pipeline

Merck's $6.7bn cash acquisition of Terns Pharmaceuticals last week, also targeting a rare oncology indication, establishes a clear sequential pattern of large-cap pharma using balance sheets for pipeline replenishment rather than organic R&D. Two deals of this scale in five days narrows the universe of acquirable rare-disease assets and inflates premiums for remaining targets.

M&A · 2 months ago

Eli Lilly pays $115m upfront for AI drug pipeline in $2.75bn Insilico deal

Eli Lilly's AI drug discovery licensing deal with Insilico for up to $2.75bn, announced two days earlier, shows pharma capital deployment running on parallel tracks: bolt-on rare-disease acquisitions for near-term revenue and AI platform licensing for long-cycle pipeline. Both deal types are compressing available targets simultaneously, which tightens the competitive dynamic for remaining biotech assets in both categories.

Biogen acquires Apellis Pharmaceuticals for $5.6bn cash

Analysis

Connected Events

Merck buys Terns Pharmaceuticals for $6.7bn to shore up post-Keytruda pipeline

Eli Lilly pays $115m upfront for AI drug pipeline in $2.75bn Insilico deal

Further reading

Related Stories

James Murdoch's Lupa Systems acquires Vox, New York Magazine and podcast network for $300m

Google and Blackstone to form AI cloud joint venture with $5bn backing

Meta to cut 8,000 jobs and reassign 7,000 to AI roles in restructuring beginning May 20